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Background: PCDH8 is a novel tumor suppressor gene, and frequently inactivated by promoter methylation in
human cancers. However, there is little information regarding PCDH8 methylation in non-muscle invasive bladder
cancer (NMIBC). The aim of this study was to investigate the methylation status of PCDH8 in NMIBC and its clinical
significance.
Methods: The methylation status of PCDH8 in 233 NMIBC tissues and 43 normal bladder epithelial tissues was examined
by methylation-specific PCR (MSP), and then analyzed the correlations between PCDH8 methylation and clinicopatholocial
features. Subsequently, Kaplan-Meier survival analysis and Multivariate Cox proportional hazard model analysis was used
to investigate the correlation between PCDH8 methylation and prognosis of patients with NMIBC.
Results: PCDH8 methylation occurred frequently in NMIBC tissues than those in normal bladder epithelial tissues. In
addition, PCDH8 methylation significantly correlated with advanced stage, high grade, larger tumor size, tumor recurrence
and progression in NMIBC. Kaplan-Meier survival analysis revealed that patients with PCDH8 methylated have shorter
recurrence-free survival, progression-free survival and five-year overall survival than patients with PCDH8 unmethylated.
Multivariate analysis suggested that PCDH8 methylation was an independent prognostic biomarker for recurrence-free
survival, progression-free survival and five-year overall survival simultaneously.
Conclusions: PCDH8 methylation may be associated with tumor progression and poor prognosis in NMIBC and may be
used as a potential biomarker to predict the prognosis of patients with NMIBC.
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Bladder cancer is one of the most frequently diagnosed
malignancies and a common cause of cancer related death
in the human, which has become a major public health
problem in the world [1-4]. Although most of the newly
diagnosed bladder tumors are non-muscle invasive blad-
der cancer (NMIBC), the majority of these NMIBC cases
will relapse after curative transurethral resection, and
some will progress to muscle invasive disease ineluctably
[5,6]. Unfortunately, the outcome of bladder cancer is
worse with tumor progression [2]. Currently, conventional
clinicopathological factors are insufficient to predict the* Correspondence: mjg2014sjz@163.com
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Therefore, new markers are needed to predict the course
of NMIBC, which may be helpful in the making of treat-
ment strategies [7-10]. As most of other human cancers,
the initiation and progression of bladder cancer associates
with the accumulation of genetic and epigenetic changes;
DNA methylation is the most common and best-
characterized epigenetic change in bladder cancer, which
inactivates tumor suppressor genes and may be used as
potential biomarker [9,10].
PCDH8 is a member of protocadherin subfamily, which
belongs to cadherin super-family [11-16]. The protocadher-
ins commonly have six ertracellular cadherin domains, a
transmembrane domain, and different cytoplasmic domains.
The protocadherins play important roles not only in cell-
cell adhesion, but also in signal transduction, growth. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Representative MSP results for PCDH8 methylation
in tumor-derived DNA samples from patients with NMIBC.
W: water; P: positive control; N: negative control; M: methylated;
U: unmethylated. Cases 71, 73 and 74 exhibited PCDH8 methylation.
Case 72 exhibited PCDH8 unmethylation.
Table 1 The methylation status of PCDH8 in NMIBC and
normal bladder epithelial (NBE) tissues
Group M (%) U (%) P
NMIBC 128 (54.9) 105 (45.1) <0.0001
NBE 0 (0.0) 43 (100.0)
M: Methylation; U: Unmethylation.
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[11-16]. In recent years, studies reported that protocadheins
often inactivated by promoter methylation in human cancers,
and the aberrant promoter methylation can be used as po-
tential biomarker for tumor diagnosis, surveillance, or
prognosis, such as PCDH8, PCDH10, PCDH17, and PCDH20,
which are considered as tumor suppressor genes in tu-
mors [11-21]. Recently, the inactivation of PCDH8 caused
by promoter methylation has been reported in human can-
cers, including bladder cancer [13-16]. In our previous
study, we found that PCDH8 promoter methylation occurs
frequently in bladder cancer, and associates with poor out-
comes of bladder cancer patients [13]. However, our previ-
ous study included both non-muscle invasive and muscle
invasive disease, and the clinical significance of PCDH8
promoter methylation in NMIBC remains largely unclear.
In the present study, the methylation status of PCDH8
in NMIBC and normal bladder epithelial tissues was ex-
amined using MSP. Then we investigated the correlation
between PCDH8 methylation status and clinicopathologic
parameters in NMIBC cases. Moreover, we assessed the
influence of PCDH8 methylation on the outcomes of
NMIBC patients to evaluate its clinical significance.
Materials and methods
Patient tissue specimens
A total of 233 patients with bladder cancer who had a trans-
urethral resection of bladder tumor between January 2004
and January 2008 at the Third Hospital of Hebei Medical
University were recruited. All patients were histopathologic-
ally diagnosed as non-muscle invasive bladder transitional
cell carcinoma for the first time, and they did not receive
preoperative anti-cancer therapy. In addition, the normal
bladder epithelial tissues obtained from 43 inpatients with
bladder stone were also collected as controls; these samples
were examined pathologically to exclude the possibility of
incidental tumors. The tissue samples were immediately fro-
zen in liquid nitrogen after resection and stored at -80°C
until examined. The bladder cancers were graded and staged
according to 1973 WHO grading system and 2002 TNM
classification [22,23]. Tumor therapy and follow up strat-
egies were performed according to international guidelines
[22-24] Recurrence was defined as a new tumor observed in
the bladder after initial curative resection and progression
was defined as a disease with a higher TNM stage when
relapsed [25]. Follow-up continued until the death of the
patient or to 60 months if the patient remained alive.
This study was approved by the ethics committee of Third
Hospital of Hebei Medical University, and written informed
consent was obtained from all of the participants.
DNA extraction, bisulfite modification and MSP
Genomic DNA from the tissue samples was extracted
using DNeasy Tissue Kit (Qiagen, Valencia, CA) followingthe manufacture’s instructions. The quality of extracted
DNA was assessed using NanoDrop ND-1000 (Thermo
Fisher Scientific, Waltham, USA). The extracted DNA was
treated with bisulfite using EpiTect Bisulfite Kit (Qiagen,
Valencia, CA) according to the manufacture’s protocol.
The bisufite modifited DNA was then used for MSP.
The methylation status of PCDH8 was detected using
primers specific for PCDH8 unmethylated and methylated
sequences respectively, as our reported previously [18].
The following primers were used: unmethylated: forward
5’- GGTGGTTATTGGTTATTTGGTTT-3’ and reverse
5’- CCAACAAACTCTAAAAACACACA-3’; methylated:
forward 5’- CGGTTATTGGTTATTCGGTTCC-3’ and re-
verse 5’- ACGAACTCTAAAAACGCGCG -3’. The PCR
amplification of the modified DNA consisted of one cycle
of 95°C for 5 min, 40 cycles of 95°C for 30 s, 60°C for 30 s,
and 72°C for 30 s, and 1 cycle of 72°C for 5 min. Water
blanks were included with each assay, in vitro methylated
DNA and unmethylated DNA (New England Biolabs,
Beverly, MA, USA) was used as methylation and
unmethylation positive control. PCR products were sepa-
rated in 2% agarose gel, stained with ethidium bromide,
and visualized under ultraviolet illumination for analysis.
Samples were scored as methylation positive when meth-
ylated alleles were present in the methylated DNA lane
and methylation negative when bands were present only
in the unmethylated DNA lane [18].
Statistical analysis
Statistical analysis was conducted using SAS version 8.0
(SAS Institute, Cary, N.C., USA). Fisher’s exact test was
used to assess the difference of PCDH8 methylation status
between NMIBC patients and controls. Chi-square test
was used to assess the relationship between PCDH8
methylation and clinicopathologic features. Kaplan-Meier
survival analysis and log-rank test were used to assess
Table 2 Relationship between PCDH8 methylation and
clinicopathological characteristics in NMIBC (n = 233)
Features Variables No. M (%) U (%) P
Age 65 86 46(53.5) 40(46.5) 0.7342
>65 147 82(55.8) 65(44.2)
Sex Male 161 94(58.4) 67(41.6) 0.1135
Female 72 34(47.2) 38(52.8)
Number Single 142 82(57.8) 60(42.2) 0.2814
Multiple 91 46(50.6) 45(49.4)
Size ≤3 cm 139 69(49.6) 70(50.4) 0.0482
>3 cm 94 59(62.8) 35(37.2)
Grade G1/ G2 144 67(46.5) 77(53.5) 0.0010
G3 89 61(68.5) 28(31.5)
Stage Ta 95 43(45.3) 52(54.7) 0.0138
T1 138 85(61.6) 53(38.4)
Recurrence No 127 40(31.5) 87(68.5) <0.0001
Yes 106 88(83.0) 18(17.0)
Progression No 175 80(45.7) 95(54.3) <0.0001
Yes 58 48(82.8) 10(17.2)
M: Methylation; U: Unmethylation.
Figure 3 Correlations between PCDH8 methylation and
progression-free survival in NMIBC patients. Patients with PCDH8
methylated showed significantly shorter progression-free survival
than patients without (P < 0.0001, log-rank test).
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free survival and five-year overall survival between pa-
tients with PCDH8 methylated and unmethylated.
Multivariate Cox proportional hazard model analysis
was used to assess the independent prognostic effect of
PCDH8 methylation. A two-sided p value < 0.05 was
considered statistically significant.
Results
The methylation status of PCDH8 in NMIBC and normal
bladder epithelial tissues
In the current study, the methylation status of PCDH8 in
NMIBC and normal bladder epithelial tissues was examinedFigure 2 Correlations between PCDH8 methylation and
recurrence-free survival in NMIBC patients. Patients with PCDH8
methylated showed significantly shorter recurrence-free survival than
patients without (P < 0.0001, log-rank test).by MSP. We found that PCDH8 methylation occurred in
128 (54.9%) patients with NMIBC (Figure 1). However, no
methylation was detected in controls, and the difference
between these two groups was statistically significant. The
result is shown in Table 1.Relationship between PCDH8 methylation and
clinicopathological characteristics
The main purpose of this study was to investigate the
clinical significance of PCDH8 methylation in NMIBC,
so we investigated the relationships between PCDH8
methylation and clinicopathological features in bladder
cancer. The association of PCDH8 methylation with the
clinicopathological features is summarized in Table 2. The
promoter methylation of PCDH8 in NMIBC tissues was
correlated with, advanced stage (P = 0.0138), high grade
(P = 0.0010), larger tumor size (P = 0.0482), tumor recur-
rence (P < 0.0001) and tumor progression (P < 0.0001) sig-
nificantly. However, the promoter methylation of PCDH8
was not correlated with age, gender, and tumor number.Figure 4 Correlations between PCDH8 methylation and
five-year overall survival in NMIBC patients. Patients with PCDH8
methylated showed significantly shorter five-year overall survival
than patients without (P = 0.0177, log-rank test).
Table 3 The predictive value of PCDH8 methylation for the recurrence-free survival in non muscle invasive bladder
cancer (n = 233)
Variable Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
PCDH8 methylation (M vs. U) 7.083 2.576-14.621 <0.0001 4.739 1.872-12.053 <0.0001
Age (>65 vs. ≦65) 1.241 0.768-5.724 0.7931
Sex (Male vs. Female) 0.926 0.753-3.761 0.8541
Number (Multiple vs. Single) 1.411 0.674-12.653 0.7244
Size (>3 cm vs. ≤3 cm) 1.537 0.687-10.431 0.7196
Grade (G3 vs. G1/G2) 5.067 1.933-10.763 0.0006 2.055 1.644-8.431 0.0137
Stage (T1 vs. Ta) 2.073 1.027-9.754 0.0176 1.371 0.824-6.084 0.0735
HR: Hazard Ratio; M: Methylated; U: unmethylated.
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outcome of NMIBC
To examine if PCDH8 promoter methylation is a potential
predictor of the prognosis in NMIBC, the recurrence-free
survival, progression-free survival and five-year overall
survival was analyzed, and the NMIBC patients was di-
vided into two subgroup according to PCDH8 methyla-
tion status. Kaplan-Meier survival analysis and log-rank
test suggested that NMIBC patients with PCDH8 methyl-
ated had significantly shorter recurrence-free survival
(P < 0.0001; Figure 2), progression-free survival (P < 0.0001;
Figure 3) and five-year overall survival (P = 0.0262; Figure 4)
than patients with PCDH8 unmethylaed respectively.
Moreover, multivariate Cox proportional hazard model
analysis indicated that PCDH8 promoter methylation in tis-
sues was an independent predictor of shorter recurrence-
free survival (P < 0.0001; Table 3), progression-free survival
(P =0.0036; Table 4) and five-year overall survival (P = 0.0015;
Table 5).
Discussion
Bladder cancer is a multifaceted disease with clinical out-
come difficult to predict, and the morphological similar
tumors can behave differently [2]. Thus, new biomarkersTable 4 The predictive value of PCDH8 methylation for the p
cancer (n = 233)
Variable Univariate analysis
HR 95% CI
PCDH8 methylation (M vs. U) 4.893 1.872-9.433
Age (>65 vs. ≦65) 0.896 0.873-5.215
Sex (Male vs. Female) 1.213 0.855-5.217
Number (Multiple vs. Single) 1.322 0.729-8.537
Size (>3 cm vs. ≤3 cm) 1.227 0.579-11.460
Grade (G3 vs. G1 / G2) 3.679 1.463-7.754
Stage (T1 vs. Ta) 1.625 0.893-6.792
HR: Hazard Ratio; M: Methylated; U: Unmethylated.are needed to predict the outcome of bladder cancer, in
addition to commonly used clinicopathological parame-
ters [2]. In recent years, more and more researchers are
interested in the aberrant methylation of different genes in
bladder cancer for some reasons [9,10,26]. Firstly, aberrant
methylation in the promoter regions of the tumor sup-
pressor genes at CPG islands has been recognized as one
of the hallmarks of human cancers and associated with
silence of gene expression, which may be used as poten-
tial biomarker in human cancers [27-31]. Secondly,
DNA methylation can be reversed by demethylating
agents, which may used as effective therapeutic target.
PCDH8 is a novel tumor suppressor gene, and com-
monly inactivated by aberrant promoter methylation in
human cancers [11-16]. In the current study, we are fo-
cused on the methylation of PCDH8 in NMIBC, and
clarified its clinical significance.
In this study, the methylation status of PCDH8 in
NMIBC tissues and normal bladder epithelial tissues was
examined by MSP. MSP is a rapid, simple, sensitive, spe-
cific, cost effective method for methylation detection, and
allowing the rapid examination of multiple samples, which
is convenient for routine clinical use [32,33]. We found
that PCDH8 methylation occurred frequently in NMIBCrogression-free survival in non muscle invasive bladder
Multivariate analysis
P HR 95% CI P





0.0017 1.874 1.237-6.873 0.0233
0.0614
Table 5 The predictive value of PCDH8 methylation for the five-year overall survival in non muscle invasive bladder
cancer (n = 233)
Variable Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
PCDH8 methylation (M vs. U) 4.653 1.237-7.314 <0.0001 3.017 1.542-8.251 0.0015
Age (>65 vs. ≦65) 1.135 0.779-6.273 0.3471
Sex (Male vs. Female) 0.874 0.645-3.228 0.7361
Number (Multiple vs. Single) 1.054 0.798-6.417 0.3784
Size (>3 cm vs. ≤3 cm) 1.253 0.913-10.257 0.3095
Grade (G3 vs. G1 / G2) 3.876 1.643-6.024 0.0021 1.852 1.144-5.964 0.0324
Stage (T1 vs. Ta) 1.015 0.792-7.572 0.4338
HR: Hazard Ratio; M: Methylated; U: Unmethylated.
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der epithelial tissues. This finding indicated that PCDH8
methylation is tumor specific, may be involved in the
tumorigenesis of bladder cancer, and giving the possibility
to investigate its clinical significance in NMIBC. Subse-
quently, we investigated the associations between PCDH8
methylation and clinicopathological factors in NMIBC
cases only. PCDH8 methylation was significantly associ-
ated with higher grade, advanced stage, larger tumor size,
and multiple tumor number. These factors are considered
as risk factors for the progression of bladder cancer [2-5].
Therefore, PCDH8 may be involved in the progression of
NMIBC. Amazingly, when we correlated PCDH8 methyla-
tion to the recurrence and progression of NMIBC, we
found that PCDH8 methylation significantly associated
with the recurrence and progression of NMIBC after ini-
tial adequate treatment. Our data suggested that PCDH8
methylation may be correlated with poor outcome of pa-
tients with NMIBC, and may be a potential predictive bio-
marker for the prognosis.
To further investigate the prognostic value of PCDH8
methylation in NMIBC, the recurrence-free survival,
progression-free survival and five-year overall survival
was analyzed according to the methylation status of
PCDH8 in tumor samples. Kaplan-Meier survival ana-
lysis and log-rank test demonstrated that patients
with PCDH8 methylation had significantly unfavorable
recurrence-free survival, progression-free survival and
five-year overall survival than patients with PCDH8
unmethylated. Moreover, multivariate Cox proportional
hazard model analysis indicated that PCDH8 methyla-
tion was an independent prognostic biomarker for
recurrence-free survival, progression-free survival and
five-year overall survival simultaneously. These results
indicate that PCDH8 methylation plays an important
role in the initiation and progression of NMIBC, is sig-
nificantly correlated with poor prognosis independently.
Furthermore, the significant role of PCDH8 methyla-
tion in NMIBC indicates the possibility to make it as apotential therapeutic target. Previous studies have re-
vealed that the methylation status of PCDH8 in tumor
cell lines can be reversed by demethylating agents and
restore PCDH8 expression. The restoration of PCDH8
expression plays crucial role in the inhabitation of tumor
cell proliferation, migration and invasion, which are all
crucial factors of tumor progression [14-16]. Taken to-
gether, these findings suggest the possibility to make
PCDH8 methylation a potential target for anticancer
therapy in NMIBC.
Conclusions
In conclusion, PCDH8 methylation occurred frequently in
NMIBC, and correlated higher grade, advanced stage, lar-
ger tumor size, tumor recurrence and progression. More-
over, PCDH8 methylation was an independent prognostic
biomarker for recurrence-free survival, progression-free
survival and five-year overall survival simultaneously.
Thus for NMIBC patients with PCDH8 methylated in
tumor samples after initial transurethral resection of pri-
mary tumor more aggressive adjunctive therapy should be
considered, in order to achieve better prognosis. In
addition, PCDH8 methylation may be used as an effective
therapeutic target in NMIBC. However, our study was
limited by relative small sample size in mono-center, and
future studies with larger sample size in multiple centers
are needed to confirm our findings before used routinely
in clinical practice.
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